

1 ***Mycobacterium tuberculosis*-specific T cell responses are impaired during late**  
2 **pregnancy with elevated biomarkers of tuberculosis risk postpartum**

3  
4 Authors: Aparajita Saha<sup>1,2</sup>, Jaclyn Escudero<sup>2</sup>, Troy Layouni<sup>3</sup>, Barbra Richardson<sup>2,4</sup>, Sharon  
5 Hou<sup>2</sup>, Nelly Mugo<sup>5</sup>, Andrew Mujugira<sup>2,6</sup>, Connie Celum<sup>1,2,7</sup>, Jared M. Baeten<sup>2,8</sup>, Jairam  
6 Lingappa<sup>1,2,4</sup>, Grace C. John-Stewart<sup>1,2,7,9</sup>, Sylvia M. LaCourse<sup>1,2\*</sup>, Javeed A. Shah<sup>1,2,3\*</sup>.

7 \*Both authors contributed equally

8  
9 Affiliations:

10 <sup>1</sup> Department of Medicine, University of Washington

11 <sup>2</sup> Department of Global Health, University of Washington

12 <sup>3</sup> VA Puget Sound Health Care System

13 <sup>4</sup> Department of Biostatistics, University of Washington

14 <sup>5</sup> Kenya Medical Research Institute, Nairobi, Kenya

15 <sup>6</sup> Infectious Diseases Institute, Makerere University, Kampala, Uganda

16 <sup>7</sup> Department of Pediatrics, University of Washington

17 <sup>8</sup> Gilead Sciences, Foster City

18 <sup>9</sup> Department of Epidemiology, University of Washington

19  
20 Corresponding author: Javeed A. Shah, [jashah@uw.edu](mailto:jashah@uw.edu); 206-543-8728

21  
22 Author Contributions: AS: contributed to the design, data acquisition, analysis, and manuscript  
23 preparation. JE: data analysis, manuscript preparation, sample collection and transport, TL:  
24 statistical analysis, software, BR: data analysis, statistical support, manuscript editing; SH/HH:  
25 sample transport, sample storage, database management, NM/AM: sample collection/storage,  
26 participant enrollment, CC/JB: cohort enrollment, funding, sample storage, manuscript editing,  
27 JL: cohort enrollment, sample storage, funding, manuscript editing, GJS: experimental design,  
28 data analysis, funding, manuscript editing, SL: experimental design, data analysis, grant  
29 funding, manuscript preparation and editing; JAS: experimental design, data analysis, grant  
30 funding, manuscript preparation and editing.

31  
32 Grant Support: NICHD R21-HD098746, NIAID K23-AI120793, R01-AI136921,  
33 Bill & Melinda Gates Foundation 26469, 41185, and 47674

34  
35 Short Title: Pregnancy and Mtb T cell responses

36  
37 Descriptor: 11.4 Mycobacterial Disease: Host Defenses

38  
39 Total Word Count: 3534

40  
41 This title has an online data supplement which is accessible from this issue's table of content  
42 online at [www.atsjournals.org](http://www.atsjournals.org).

43

44 **Abstract**

45 Rationale: Pregnancy is a risk factor for progression from latent tuberculosis infection (LTBI) to  
46 symptomatic tuberculosis (TB). However, how dynamic immunologic changes in pregnancy  
47 influence immune responses to *M. tuberculosis* (Mtb) is unknown.

48 Objectives: We performed a detailed characterization of Mtb-specific T cell responses of women  
49 at high risk for Mtb infection, leveraging a biorepository of longitudinally samples collected  
50 before, during, and after pregnancy in high HIV/TB burden settings.

51 Methods: We used specimens collected from women who became pregnant while enrolled in a  
52 randomized controlled trial of pre-exposure prophylaxis for HIV prevention. We measured Mtb-  
53 specific cytokines, CCR7 and CD45RA memory markers, and overall CD4+ and CD8+ T cell  
54 activation from 49 women using COMPASS, a Bayesian statistical method for evaluating overall  
55 antigen-specific T cell responses measured by flow cytometry.

56 Measurements and Main Results: 22 LTBI+ women, defined by flow cytometry, demonstrated  
57 significantly diminished Mtb-specific CD4+ cytokine responses in the third trimester (COMPASS  
58 score (PFS) 0.07) compared before (PFS 0.15), during (PFS 0.13 and 0.16), and after  
59 pregnancy (PFS 0.14;  $p = 0.0084$ , Kruskal-Wallis test). Paradoxically, Mtb-specific CD8+  
60 cytokine responses and nonspecifically activated CD38+HLA-DR+CD4+ T cells increased  
61 during late pregnancy. Nonspecific T cell activation, a previously validated biomarker for  
62 progression from LTBI to TB disease, was increased in LTBI+ women postpartum, compared  
63 with LTBI- women.

64 Conclusions: Pregnancy-related functional T cell changes were most pronounced during late  
65 pregnancy. Mtb-specific T cell changes during pregnancy and postpartum, increases in immune  
66 activation may contribute to increased risk for TB progression in the postpartum period.

67 Abstract Word Count: 245

68 Keywords: *M. tuberculosis*, pregnancy, T cells, T cell memory, T cell activation

69 **Introduction**

70 Tuberculosis (TB) disease in pregnancy and postpartum is associated with poor  
71 maternal and infant outcomes (1, 2). Recent large cohort studies demonstrate that pregnancy is  
72 associated with increased rates of tuberculosis disease (TB) up to six months postpartum (3, 4).  
73 However, the immune mechanisms underpinning this observation are not clear. Successful  
74 pregnancy requires dynamic alteration of the local immune environment (5-7). These  
75 adaptations to fetal development are accompanied by cell-specific systemic immune alterations  
76 (8). Pathogen-specific responses may be influenced by these systemic immune changes, which  
77 can alter disease risk (9-11). Understanding pathogen-specific changes to the immune  
78 response during pregnancy may improve efforts to prevent and control disease.

79

80 T cell responses are a critical aspect of Mtb host defense. Multiple lines of evidence,  
81 including studies in mouse and nonhuman primate studies of CD4+ T cell knockout or depletion,  
82 human genetic studies, and observational studies during HIV infection demonstrate that CD4+ T  
83 cells are essential for Mtb control (12-16). Prior data suggests that IFN $\gamma$  responses in CD4+ T  
84 cells are essential for Mtb protection (17). The frequency of CD4+ T cells simultaneously  
85 producing IL-2, TNF, and IFN $\gamma$  (e.g., that are polyfunctional) is correlated with Mtb protection  
86 (18). Other T cell phenotypes, such as central memory cells (Tcm) and CD8+ T cells, may  
87 contribute to Mtb host defense (19-22). Conversely, increased total numbers of nonspecifically  
88 activated HLA-DR+CD4+ T cells are a correlate of TB progression (23, 24). Since studies of  
89 pregnancy commonly begin enrollment during the first or second trimester of pregnancy, they  
90 are often unable to capture immune variation prior to and earlier in pregnancy. We leveraged a  
91 unique biorepository of samples and data collected longitudinally before, during, and after  
92 pregnancy from women in sub-Saharan Africa enrolled in a randomized controlled trial of pre-

93 exposure prophylaxis for HIV prevention to evaluate the effects of various stages of pregnancy  
94 on Mtb-specific T cell responses.

95

## 96 **Methods**

### 97 *Study Population*

98 The protocol for this study was approved by the University of Washington Human Subjects  
99 Review Committee and ethics review committee at each study site. All participants provided  
100 written informed consent in English or their native language. The Partners PrEP Study was a  
101 randomized clinical trial of antiretroviral pre-exposure prophylaxis (PrEP) in HIV serodiscordant  
102 couples (25). 4758 total participants were enrolled from 9 sites in Kenya and Uganda between  
103 2007 and 2012. Partners with HIV and CD4 cell count  $\geq 250$ , without history of AIDS-defining  
104 diagnosis or current use of antiretroviral therapy (ART) were eligible. Participants without HIV  
105 underwent monthly HIV testing from the parent trial and had urine pregnancy testing at  
106 enrollment and monthly thereafter; women living with HIV (WLHIV) had urine collected quarterly.  
107 WLHIV not already on ART who became pregnant were referred for prevention of maternal to  
108 child transmission services. Participants were eligible for this analysis if they had at least two  
109 samples available within 6 months prior to and during incident pregnancy. If available, additional  
110 samples were tested from within 6 months postpartum. (**Figure 1A**). For participants with only  
111 two timepoints available (before and during pregnancy), paired testing was done only on  
112 participants with pregnancy samples from  $\geq 20$  weeks gestation after interim evaluation of data  
113 from participants with three time points samples. WLHIV received antiretrovirals for prevention  
114 of maternal to child transmission of HIV, but not for treatment based on the guidelines at the  
115 time.

116

### 117 *Statistical Analysis*

118 We used the R package COMPASS to analyze the overall cytokine response of CD4+ and  
119 CD8+ T cells and to determine cytokine-producing subsets. COMPASS uses a Bayesian  
120 hierarchical framework to model all observed cell subsets and select those most likely to have  
121 antigen-specific responses (26, 27). COMPASS provided a functional score (FS), which is the  
122 proportion of antigen specific subsets detected among all possible ones, and polyfunctional  
123 score (PFS), which is similar, but weighs the different subsets to favor subsets with higher  
124 degrees of functionality. Our primary outcome of interest was the COMPASS PFS from CD4+  
125 and CD8+ T cells of LTBI+ women with preexisting T cell responses against Mtb, restimulated  
126 with pooled peptides from the Mtb-specific antigens ESAT-6 and CFP10. Differences in median  
127 values were compared among timepoints of interest using Kruskal-Wallis tests as the primary  
128 analysis, followed by Dunn's test to compare individual groups. Samples from women with and  
129 without HIV were measured together except where indicated.

130

## 131 **Results**

### 132 *Cohort characteristics and timing of sample collection*

133 We identified 70 participants with incident pregnancy. 49 of these met criteria for this  
134 study, with paired samples collected during pregnancy and another, collected less than 6  
135 months prior to the pregnancy. 17 participants had samples collected from 3 timepoints (pre-,  
136 during-, and post-pregnancy). 32 participants had samples collected before and during  
137 pregnancy (**Figure 1A**). A total of 117 samples with evaluable results were analyzed; 48 pre-  
138 pregnancy (median 18.7 weeks [IQR 12.4-22.2]), 47 during pregnancy, (median 26.9 weeks  
139 gestation [IQR 12.7-30.9]); 22 post-partum (median 23.1 weeks [IQR 18.4-39.6]). The median  
140 age of study participants was 26.4 years (IQR 23.2-31.1); 36.7% (18/49) were WLHIV with  
141 median CD4 766 cells/mm<sup>3</sup> [IQR 507-1070]) (**Table 1**).

142

### 143 *Identification of LTBI+ participants using flow cytometry*

144 We identified individuals with LTBI using their first evaluable sample using a flow-based  
145 assay as TST or IGRA were not performed during the original trial. We defined individuals as  
146 LTBI+ if their proportion of the frequency of IFN $\gamma$ +CD4+ T cells doubled after ESAT-6 and CFP-  
147 10 pooled peptide stimulation compared to DMSO. This measurement correlates well with  
148 commercial IGRA tests (28-31). 22/49 (45%) individuals were LTBI+ by this measure (**Figure**  
149 **1B**). We found that increasing the threshold for positivity to three-fold above background  
150 reduced the proportion of LTBI+ individuals slightly, from 22 (44%) to 19 (41%). These  
151 observations are similar in frequency to other studies of women of childbearing age in regions  
152 with high Mtb burden (32). We used the initially identified more inclusive cutoff to ensure we  
153 identified all individuals with pre-existing immune responses to Mtb. We identified three  
154 individuals who were LTBI- at baseline but LTBI+ by their pregnancy visit. In these situations,  
155 we included these individuals as LTBI+ from their first positive result onward.

156

157 *CD4+ and CD8+ T cell frequency is consistent before, during, and after pregnancy*

158 Our primary study objective was to identify the overall changes to the T cell response  
159 using samples collected before, during, and after pregnancy among LTBI+ women. We first  
160 identified the frequency of CD4+ and CD8+ T cells from samples collected before, during, and  
161 after pregnancy (gating shown in **Figure S1A**). The frequency of CD4+ and CD8+ T cells was  
162 similar over these time points (**Figure 1B-C**). In WLHIV, the frequency of CD4+ T cells was  
163 lower than in women without HIV, irrespective of pregnancy status (**Figure S1B**) and CD8+ T  
164 cell frequency was increased (**Figure S1C**). COMPASS FS and PFS of CD4+ T cells from all  
165 samples strongly correlated with our LTBI measurements (**Figure 1E-F**).

166

167 *Mtb-specific CD4+ T cells polyfunctional responses decreased during the third trimester of*  
168 *pregnancy*

169 Mtb induces a polyfunctional T cell response that may act independently of IFN $\gamma$ , and  
170 these cells are critical for Mtb control (33). In Mtb-specific CD4<sup>+</sup> T cells, PFS was significantly  
171 different before, during, and after pregnancy (**Figure 2A**, gating in Figure S2;  $p = 0.0084$ ,  
172 Kruskal-Wallis test). PFS was significantly decreased in the third trimester compared with pre-  
173 pregnancy ( $p = 0.0005$ ), second trimester ( $p = 0.0034$ ) and post-pregnancy ( $p < 0.017$ ), but not  
174 during the first trimester ( $p = 0.099$ ; **Figure 2A**). FS results were similar to PFS (**Figure 2B**). We  
175 detected fewer Mtb-specific cytokine-producing subsets during third trimester, and very few  
176 subsets producing multiple cytokines simultaneously (COMPASS heatmaps shown in **Figure**  
177 **S3A**). We noted diminished single cytokine responses during the third trimester in IL-2+CD4<sup>+</sup>  
178 cells compared with the second trimester (**Figure S3B**;  $p = 0.026$ ) which trended lower  
179 compared with pre-pregnancy ( $p = 0.13$ ), first trimester ( $p = 0.12$ ) and post-pregnancy ( $p =$   
180  $0.09$ ). CD4+TNF<sup>+</sup> or CD4+IFN $\gamma$ <sup>+</sup> responses were similar across pregnancy (**Figure S3C-D**).  
181 Therefore, using COMPASS, we were able to detect changes to Mtb-specific T cell responses  
182 that may be clinically important but not immediately detectable by analyzing single cytokines  
183 separately.

184

#### 185 *CD4<sup>+</sup> T cell responsiveness to a mitogen is altered during the third trimester*

186 Clinical laboratory tests for LTBI include mitogen controls to assess overall T cell  
187 reactivity; impacts to mitogen induced CD4<sup>+</sup> and CD8<sup>+</sup> T cell responses during pregnancy  
188 directly alter LTBI diagnostic test performance (34). We compared T cell responses after  
189 stimulation with phorbol 12-myristate 13-acetate and ionomycin (PMA/ionomycin) over  
190 pregnancy in all study participants. We evaluated these T cell responses using traditional flow  
191 cytometry analysis, not COMPASS, as COMPASS is designed to detect antigen specific  
192 responses observed at low frequency. The frequency of IL2+CD4<sup>+</sup> T cells responding to  
193 PMA/ionomycin were significantly changed over the duration of pregnancy (**Figure 3A**,  $p$

194 <0.0001, Kruskal-Wallis test). IL-2+CD4+ responses in the third trimester were increased  
195 compared to pre-pregnancy ( $p = 0.022$ ), first trimester ( $p = 0.0006$ ) and post-pregnancy ( $p <$   
196  $0.0001$ ). TNF+CD4+ responses were also significantly increased during the third trimester  
197 compared to first trimester ( $p = 0.0073$ ) and post-pregnancy ( $p = 0.0002$ ; **Figure 3B**,  $p = 0.0011$   
198 overall). IFN $\gamma$ +CD4+ cells decreased across pregnancy ( $p = 0.0036$ ). The third trimester  
199 response was significantly diminished compared to pre-pregnancy ( $p = 0.016$ ), first trimester ( $p$   
200  $= 0.026$ ), second trimester ( $p = 0.049$ ), and post-pregnancy (**Figure 3C**;  $p = 0.0001$ ). IL-2+,  
201 TNF+, and IFN $\gamma$ + CD4+ T cell frequencies were each significantly different before and after  
202 pregnancy ( $p = 0.006$ ,  $p = 0.008$ , and  $p = 0.04$ , respectively), suggesting that systemic immune  
203 alterations of pregnancy begin during the first trimester and persist for weeks to months after  
204 birth. These data demonstrate distinct patterns of CD4+ T cell activation across pregnancy as  
205 compared to Mtb-specific T cells.

206

207 *Mtb-specific CD8+ T cells increase in activity during the second and third trimester of pregnancy*

208 CD8+ T cells contribute to Mtb host defense and are measured in LTBI diagnostic tests  
209 (35, 36), but little is known about how pregnancy impacts Mtb-specific CD8+ T cell responses.  
210 We found low but detectable Mtb-specific CD8+ T cell cytokine responses in most samples from  
211 LTBI+ participants (**Figure S2**, gating strategy). The PFS and FS in CD8+ T cells changed  
212 significantly over the course of pregnancy (**Figure 4A-B**;  $p = 0.0033$  and  $p = 0.038$  respectively,  
213 Kruskal-Wallis test). Median PFS in CD8+ T cells was nearly undetectable before pregnancy  
214 and significantly increased in the second trimester compared with pre-pregnancy ( $p = 0.015$ ),  
215 the first trimester ( $p = 0.023$ ), and post-pregnancy ( $p = 0.034$ ). A similar trend was observed in  
216 FS. The complexity of the CD8+ T cell response increased during the second and third  
217 trimester, and we detected subsets producing multiple cytokines simultaneously (**Figure S4A**).  
218 We were unable to detect shifts in IL-2, TNF, and IFN $\gamma$ + CD8+ T cell responses when evaluated



219 singly, but we found a trend toward increased responses in each cytokine during the second  
220 and third trimester (**Figure S4B-D**). Taken together, Mtb-specific CD8+ T cell responses  
221 increased during the second and third trimester, while Mtb-specific CD4+ T cell responses  
222 diminished during the same period.

223

#### 224 *Mitogen-induced TNF+ CD8+ T cell responses increase during pregnancy*

225 We measured the changes in PMA/ionomycin-stimulated CD8+ T cell responses over  
226 the course of pregnancy in all participants. IL-2+CD8+ responses were unchanged by  
227 pregnancy trimester (**Figure 5D**;  $p = 0.14$ , Kruskal-Wallis test). TNF+CD8+ T cell frequency  
228 changed over the course of pregnancy (**Figure 5E**;  $p = 0.0084$ ) and increased in the third  
229 trimester compared with the first trimester ( $p = 0.015$ ) and post-pregnancy ( $p = 0.0018$ ).  
230 IFN $\gamma$ +CD8+ T cell frequencies were similar across pregnancy (**Figure 5F**). These responses  
231 were distinct from the changes observed in Mtb-specific CD8+ T cells, where multiple subsets  
232 increased in frequency during the second and third trimester.

233

#### 234 *Mtb-specific effector memory T cell populations diminish during the third trimester*

235 T cells display cell surface markers CD45RA and CCR7 as markers of T cell memory  
236 phenotype (37). Naïve (CCR7+CD45RA+), central memory (Tcm; CCR7+CD45RA-), and  
237 effector memory (Tem; CCR7-CD45RA-) T cells display distinct functional profiles and tissue  
238 homing sites, and Tcm are important for Mtb control (38-40). Naïve and Tcm produce little IFN $\gamma$ ,  
239 but Tem does not provide extended protection against disease. The frequency of total CD4+  
240 and CD8+ T cells expressing CD45RA and CCR7 did not change over pregnancy (**Figure S5A-**  
241 **C**). We evaluated CD45RA and CCR7 expression in Mtb-specific CD4+ T cells, which were  
242 ESAT-6 and CFP-10 peptide incubated, cytokine-producing, CD4+ T cells from LTBI+  
243 individuals. The proportion of Mtb-specific naïve and Tcm CD4+ T cells remained stable (**Figure**

244 **6A-B**), but we observed reduced Tem frequency during the third trimester (**Figure 6C**,  $p =$   
245  $0.037$ ; Kruskal-Wallis test) compared to pre-pregnancy ( $p = 0.049$ ), first trimester ( $p = 0.005$ ),  
246 second trimester ( $p = 0.014$ ), and postpartum ( $p = 0.031$ ). Viewed proportionally, naïve CD4+  
247 cells increased while Tem decreased during the third trimester of pregnancy compared to the  
248 first trimester, second trimester, and postpartum, without substantial changes to Tcm frequency  
249 (**Figure 6D**). We did not detect adequate Mtb-specific CD8+ T cells to evaluate T cell  
250 phenotypes in this population. In sum, Tem and IFN $\gamma$ +CD4+ cells were reduced during the third  
251 trimester, but without increases in the Tcm population, which is important for Mtb host defense  
252 and may predict worsened Mtb control.

253

#### 254 *Nonspecific T cell activation increases during pregnancy*

255 Increased nonspecific CD4+ T cell activation is a correlate of risk for developing Mtb  
256 disease (41, 42). We measured the frequency of HLA-DR+CD38+ CD4+ and CD8+ T cells  
257 across pregnancy, using “flow minus one” controls (**Figure S6A**). The frequency of HLA-  
258 DR+CD38+ CD4+ T cells significantly changed over pregnancy (**Figure 7A**;  $p < 0.0001$ ,  
259 Kruskal-Wallis test), highest in the third trimester compared to pre-pregnancy ( $p = 0.0068$ ), first  
260 trimester ( $p < 0.0001$ ), second trimester ( $p = 0.007$ ), or postpartum (**Figure 7A**;  $p < 0.0001$ ).  
261 HLA-DR+CD38+ CD8+ T cell frequency also significantly changed similarly to CD4+ T cells  
262 (**Figure 7B**;  $p < 0.0001$ , Kruskal-Wallis test). In both CD4+ and CD8+ T cells, activation markers  
263 decreased from pre-pregnancy to the first trimester, and WLHIV demonstrated the greatest T  
264 cell activation throughout pregnancy. Therefore, T cell activation decreases at the outset of  
265 pregnancy, then increases over time until delivery.

266 We leveraged the observation that CD4+ T cell activation is a biomarker for TB risk to  
267 evaluate if the immune changes of pregnancy might increase the risk for TB progression from  
268 asymptomatic to symptomatic disease. We hypothesized that selective increases in nonspecific  
269 T cell activation would be present in LTBI+ women after pregnancy due to their increased risk

270 for postpartum Mtb progression but not for LTBI- women. Pre-pregnancy, the proportion of  
271 HLADR+CD38+CD4+ T cells was equivalent between LTBI- and LTBI+ individuals (**Figure 7C**).  
272 Postpartum, LTBI+ individuals demonstrated significantly higher HLA-DR+CD38+ CD4+ T cells  
273 as compared to LTBI- individuals (**Figure 7D**;  $p = 0.0026$ , Mann-Whitney test). Immune  
274 changes of pregnancy in LTBI+ individuals may substantially contribute to overall T cell  
275 activation in the postpartum period and predict increased risk for TB progression.

276

## 277 **Discussion**

278 In this study, we performed a comprehensive analysis of pregnancy stage on Mtb-  
279 specific T cell phenotypes in sub-Saharan African women including women living with HIV.  
280 These data are, to our knowledge, the first longitudinal assessment of systemic T cell responses  
281 to Mtb in pregnancy that includes samples collected prior to pregnancy. Taken in sum, we found  
282 that late pregnancy is associated with multiple changes to Mtb-specific T cell function: 1) overall  
283 Mtb-specific CD4+ T cell responses diminished and simplified; 2) Mtb-specific CD4+ Tem, which  
284 are cells that strongly produce IFN $\gamma$ , decreased (37); 3) Mtb-specific CD8+ T cell responses  
285 increased, and 4) nonspecific T cell activation increased. (**Figure 8**). Nonspecific T cell  
286 activation increased in LTBI+ individuals compared to LTBI- individuals postpartum, despite  
287 being equivalent pre-pregnancy. Increased nonspecific T cell activation, a correlate of risk for  
288 Mtb disease in LTBI+ individuals, supports the observation that TB risk increases in the early  
289 postpartum period (41). Together, late pregnancy induces complex changes in the known T cell  
290 response to Mtb that have been associated with TB progression in other populations, and we  
291 found that LTBI+ women develop increased correlates of risk for TB in the immediate  
292 postpartum period.

293

294 We observed distinct changes between Mtb-specific and more generalized mitogen  
295 (PMA/ionomycin)-induced T cell cytokine responses. These results have direct implications

296 toward the performance of LTBI diagnostics in pregnant women. Mtb-specific CD4+ T cell  
297 responses decreased during the third trimester but increased in the second trimester, and Mtb-  
298 specific CD8+ T cell responses were low but increased during the second and third trimester.  
299 By contrast, overall mitogen responses in CD4+ T cells, especially IL-2 responses, increased  
300 during late pregnancy. In other cohorts, discordance between the two commonest LTBI tests,  
301 TST and IGRA, has been noted especially among women in the late second and early third  
302 trimester, which may be partly due to the changes in the immune responses of pregnancy (34,  
303 43). Part of the difference may be due to the absence of mitogen testing in most TSTs.  
304 Understanding this discordance in pregnancy may have implications for TB progression. Among  
305 those with positive IGRA but negative TST tests, Mtb-specific IL-2 responses associated with  
306 postpartum TB progression from asymptomatic infection to symptomatic disease (44). In  
307 combination, discordance between Mtb-specific and nonspecific immune responses may  
308 contribute to increased false-negative LTBI testing during the third trimester and may contribute  
309 to Mtb progression.

310

311         Conversely, we found that Mtb-specific CD8+ T cell responses increased during late  
312 pregnancy when CD4+ T cell responses were diminished. The role of CD8+ T cells in TB  
313 pathogenesis is uncertain. In children, Mtb-specific CD8+ T cell frequencies are correlated with  
314 Mtb disease (45). In animals, CD8+ T cell responses correlate strongly with Mtb bacterial  
315 burden in the lung (46, 47). CD8+ T cells recognize antigens presented on major  
316 histocompatibility complex I, which presents intracellular antigens. CD8+ T cells preferentially  
317 recognize antigen-presenting cells with an increased bacterial burden (48). During active  
318 intracellular infection, these responses may increase proportionally. It is unclear if some of these  
319 responses reflect emerging TB disease or if there are general postpartum factors that enhance  
320 CD8+ responses. These data suggest that CD8+ T cell responses may increase to compensate

321 for diminished CD4+ T cell responses but may be unable to fully reproduce CD4+ T cell immune  
322 control.

323

324         The strengths of this study include its longitudinal nature, including samples obtained  
325 before, during, and after pregnancy. Most studies of the effects of pregnancy enroll women  
326 during pregnancy and often focus on the second and third trimester, which do not capture pre-  
327 pregnancy and first trimester periods. Several T cell phenotypes change significantly between  
328 pre-pregnancy and the first trimester, and other phenotypes differed between pre-pregnancy  
329 and postpartum. Local inflammation is critical for embryonic implantation, which suggests that  
330 both local and systemic immune changes begin immediately and are prolonged post-partum  
331 (49, 50). Another strength of this study was the use of COMPASS. COMPASS analysis  
332 revealed two findings that were not observable using standard data analysis techniques. This  
333 sensitive analysis permitted us to observe the diminished complexity of the Mtb-specific CD4+ T  
334 cell response during the third trimester and increases in overall CD8+ activity. Taken together,  
335 no single cytokine response accounted for the changes to the Mtb-specific T cell response,  
336 suggesting broad changes in the functional capacity of T cells responding to antigen during the  
337 third trimester.

338

339         Weaknesses of this study include the lack of TB disease outcomes data. This study  
340 used repository samples from a trial not originally designed to evaluate TB. However, we  
341 performed detailed immune characterization of the changes to the Mtb-specific immune  
342 response across pregnancy. Importantly, LTBI+ women had increased T cell activation  
343 postpartum, when compared with LTBI- women, which is a validated biomarker of TB disease  
344 progression in other cohorts (23). IGRA or TST was not performed in the parent study, which  
345 prevents correlation with clinically validated LTBI testing. However, the method we used in this  
346 study to identify LTBI+ participants is a well-accepted alternate approach that correlates with

347 LTBI diagnosis (30, 31). Generally, flow-based testing is more sensitive to detect prior exposure  
348 to Mtb antigens than IGRA, so this approach permits us to evaluate a broader range of  
349 individual immune responses. Errors introduced by the inclusion of individuals without  
350 preexisting Mtb exposures are likely to reduce the sensitivity of this analysis to detect changes.  
351 We performed sensitivity analyses by raising the threshold for LTBI+ identification, but this did  
352 not substantially change the number of participants considered to have LTBI. Due to the limited  
353 sample size of this study, we did not perform formal analysis to investigate the impact of HIV on  
354 immune responses during pregnancy. Although HIV status was associated with reduced CD4+  
355 T cell count and increased T cell activation, we found immune changes of pregnancy were  
356 generally independent of HIV status, though direct comparisons were limited due to small  
357 sample size.

358

359 TB is the third leading cause of death among women of child-bearing age in high burden  
360 areas and is associated with morbidity and mortality in pregnant women and their children,  
361 especially among those affected by HIV (1, 43). Our study provides evidence that systemic  
362 changes in the T cell response during the third trimester may contribute to increased risk for TB  
363 progression. T cell cytokine responses are reduced and simplified, T cell memory phenotypes  
364 skewed toward naïve phenotypes, and nonspecific activation is enhanced, which all are  
365 independently associated with TB risk. Recent data suggest that isoniazid preventative therapy  
366 is associated with adverse pregnancy outcomes, with a signal that this may occur more often if  
367 initiated early in pregnancy (51). As such, late pregnancy, which is associated with key  
368 immunologic changes for TB progression, may be an advantageous time to target for shorter  
369 course regimens. Understanding host factors that place pregnant mothers at risk for TB may  
370 provide insight into optimal public health strategies for TB control in this high-risk population.

371

372 **Acknowledgements**

373 The authors would like to thank the study participants and their families. We would like to  
374 acknowledge the support of Harald Haugen on database management of clinical samples. We  
375 would also like to acknowledge the clinical teams who obtained informed consent and collected  
376 samples for this biorepository. We would also like to thank Chetan Seshadri for helpful technical  
377 conversations.

378 **Figure Legends**

379 **Figure 1. Baseline Immune Characteristics Are Stable Across Pregnancy.**

380 A) Flowchart of stored sample selection of participants with incidental pregnancies in the  
381 Partners PrEP study.

382 B) Proportion of CD4+ T cells of all CD3+ cells, by pregnancy, trimester, and HIV status. Here  
383 and throughout, Samples indicated with *black circles* are from HIV- donors, while *gold triangles*  
384 are from WLHIV here and throughout this study.

385 C) Proportion of CD8+ T cells, stratified by pregnancy, trimester, and HIV status.

386 Pre-pregnancy sample N = 49; 1<sup>st</sup> trimester N = 9, 2<sup>nd</sup> trimester N = 14; 3<sup>rd</sup> trimester N = 24;  
387 postpartum N = 22. *Black circles* indicate HIV- study participants, while *gold triangles* indicate  
388 WLHIV here and throughout this paper. Bars indicate median values. Statistical difference  
389 between CD4 and CD8+ T cells was measured by Kruskal-Wallis test with sub-analysis  
390 comparing column medians.

391 D) Fold change of the proportion of CD4+ T cells expressing IFN $\gamma$  after incubation with ESAT-6  
392 and CFP-10 pooled peptides, compared to vehicle control.

393 E) COMPASS functional score (FS), stratified by LTBI status.

394 F) COMPASS polyfunctional score (PFS), stratified by LTBI status.

395

396 **Figure 2. Mtb-specific CD4+ T cell responses are diminished during the third trimester of**  
397 **pregnancy.**

398 A) Polyfunctional scores (PFS) generated from COMPASS analysis, stratified by pregnancy  
399 trimester. *Black dots* indicate an HIV- study participant, while *gold triangles* indicate a WLHIV.  
400 Bars indicate median values. \* P < 0.05, \*\* P < 0.01, \*\*\* P < 0.001, Kruskal-Wallis test. Column-  
401 to-column comparisons are made with Dunn's test.

402 B) Functional scores (FS) generated from COMPASS analysis, stratified by pregnancy  
403 trimester. *Black dots* indicate an HIV- study participant, while *gold triangles* indicate a WLHIV.



404 Bars indicate median values. \* P < 0.05, \*\* P < 0.01, \*\*\* P < 0.001, Kruskal-Wallis test. Column-  
405 to-column comparisons are made with Dunn's test.

406

407 **Figure 3. PMA/ionomycin-stimulated CD4+ T cell cytokine responses are dynamic across**  
408 **pregnancy.**

409 A-C) Proportion of A) IL-2+CD4+, B) TNF+CD4+, or C) IFN $\gamma$ +CD4+ T cells, stratified by  
410 pregnancy status. *Black dots* indicate an HIV- study participant, while *gold triangles* indicate a  
411 WLHIV. Bars indicate median values. \* P < 0.05, \*\* P < 0.01, \*\*\* P < 0.001, GEE with estimating  
412 equation, connected by *overhead bar*.

413 D-F) Proportion of D) IL-2+CD4+, E) TNF+CD4+, or F) IFN $\gamma$ +CD4+ T cells, stratified by  
414 pregnancy trimester. *Black dots* indicate an HIV- study participant, while *gold triangles* indicate  
415 an HIV+ study participant. Bars indicate median values. \* P < 0.05, \*\* P < 0.01, \*\*\* P < 0.001,  
416 Overall significant by Kruskal-Wallis test demonstrated with top, *thick line without overhangs*.  
417 Column-to-column comparisons are made with Dunn's test and shown with *thinner bars with*  
418 *overhangs*.

419

420 **Figure 4. Mtb-specific CD8+ T cell polyfunctionality increases during the second**  
421 **trimester of pregnancy.**

422 A) Polyfunctional scores (PFS) generated from COMPASS analysis, stratified by pregnancy  
423 trimester. *Black dots* indicate an HIV- study participant, while *gold triangles* indicate a WLHIV.  
424 Bars indicate median values. \* P < 0.05, \*\* P < 0.01, \*\*\* P < 0.001, Kruskal-Wallis test. Column-  
425 to-column comparisons are made with Dunn's test. *Black dots* indicate an HIV- study  
426 participant, while *gold triangles* indicate a sample from WLHIV study participant.

427 B) Functional scores (FS) generated from COMPASS analysis, stratified by pregnancy  
428 trimester. *Black dots* indicate an HIV- study participant, while *gold triangles* indicate a WLHIV.

429 Bars indicate median values. \*  $P < 0.05$ , \*\*  $P < 0.01$ , \*\*\*  $P < 0.001$ , Kruskal-Wallis test. Column-  
430 to-column comparisons are made with Dunn's test.

431

432 **Figure 5. Cytokine responses in PMA/ionomycin-stimulated CD8+ T cells are stable**  
433 **during pregnancy.**

434 A-C) Proportion of A) IL-2+CD8+, B) TNF+CD8+, or C) IFN $\gamma$ +CD8+ T cells, stratified by  
435 pregnancy status. *Black dots* indicate an HIV- study participant, while *gold triangles* indicate an  
436 HIV+ study participant. Bars indicate median values. \*  $P < 0.05$ , \*\*  $P < 0.01$ , \*\*\*  $P < 0.001$ , GEE  
437 with estimating equation, connected by *overhead bar*.

438 D-F) Proportion of D) IL-2+CD8+, E) TNF+CD8+, or F) IFN $\gamma$ +CD8+ T cells, stratified by  
439 pregnancy trimester. *Black dots* indicate an HIV- study participant, while *gold triangles* indicate  
440 an HIV+ study participant. Bars indicate median values. \*  $P < 0.05$ , \*\*  $P < 0.01$ , \*\*\*  $P < 0.001$ ,  
441 Kruskal-Wallis test. Column-to-column comparisons are made with Dunn's test.

442

443 **Figure 6. Proportions of Mtb-specific naïve CD4+ T cells increase and effector memory T**  
444 **cells decrease during the third trimester of pregnancy.**

445 A-C) Overall proportion of A) naïve (CCR7+CD45RA+), B) central memory (T<sub>CM</sub>; CCR7+CD45RA-),  
446 and C) effector memory (T<sub>EM</sub>; CCR7-CD45RA-) among all cytokine-  
447 producing CD4+ T cells after re-stimulation with ESAT-6 and CFP-10 antigens, stratified by  
448 pregnancy status. *Black dots* indicate an HIV- study participant, while *gold triangles* indicate a  
449 sample from WLHIV study participant. \*  $P < 0.05$ , \*\*  $P < 0.01$ , \*\*\*  $P < 0.001$ , Kruskal-Wallis test.  
450 Column-to-column comparisons are made with Dunn's test.

451 D) Pie chart of Boolean-gated T helper memory phenotype frequencies, comparing the third  
452 trimester with other timepoints, connected by *overhead bar*. *Blue arc* indicates CCR7+ cells, *red*  
453 *arc* indicates CD45RA+ cells. *Red pie slice*: Naïve CD4+ T cells (Naïve); *blue pie slice*: effector

454 memory CD4+ T cells (Tem); *gray* slice: central memory T cell (Tcm); *white* slice: TEMRA cell  
455 (TEMRA). \* P < 0.05, \*\* P < 0.01, \*\*\* P < 0.001, permutation test of 10000 iterations.

456

457 **Figure 7. Nonspecific T cell activation increases during pregnancy and LTBI+ women**  
458 **demonstrate increased T cell activation postpartum**

459 A) Proportion of HLA-DR+CD38+ CD4+ T cells, stratified by pregnancy status.

460 B) Proportion of HLA-DR+CD38+ CD8+ T cells, stratified by pregnancy status.

461 C) Proportion of HLA-DR+CD38+ CD4+ T cells from samples collected pre-pregnancy, stratified  
462 by LTBI status of the participant.

463 D) Proportion of HLA-DR+CD38+ CD4+ T cells from samples collected postpartum, stratified by  
464 LTBI status of the participant. *Black dots* indicate an HIV- study participant, while *gold triangles*  
465 indicate sample from WLHIV. Thick bars correspond to overall changes (Kruskal-Wallis test).  
466 *Bars with overhangs* indicate analysis of differences between columns (Dunn's test). Bars  
467 indicate median values. \* P < 0.05, \*\* P < 0.01, \*\*\* P < 0.001, Kruskal-Wallis test. Column-to-  
468 column comparisons are made with Dunn's test in multiple group comparisons or Mann-Whitney  
469 U-test for tests between two groups.

470

471 **Figure 8. Summary of overall Mtb-specific T cell responses during differing stages of**  
472 **pregnancy.** We observed distinct changes in Mtb-specific T cell responses as compared to  
473 mitogen-stimulated T cells. Arrows indicate the overall frequency of the responses measured. A  
474 downward arrow followed by an upward arrow indicates diminished IL-2/TNF responses with  
475 simultaneous increases in IFN $\gamma$ + cell frequency, and an upward arrow followed by a downward  
476 arrow indicates increases in IL-2/TNF+ T cell frequency with decreases in IFN $\gamma$ + responses.

## References

- 477  
478  
479 1. Mathad JS, Gupta A. Tuberculosis in pregnant and postpartum women:  
480 epidemiology, management, and research gaps. *Clin Infect Dis* 2012; 55: 1532-  
481 1549.
- 482 2. Mathad JS, LaCourse SM, Gupta A. TB prevention strategies and unanswered  
483 questions for pregnant and postpartum women living with HIV: the need for  
484 improved evidence. *J Int AIDS Soc* 2020; 23: e25481.
- 485 3. Jonsson J, Kuhlmann-Berenzon S, Berggren I, Bruchfeld J. Increased risk of active  
486 tuberculosis during pregnancy and postpartum: a register-based cohort study in  
487 Sweden. *Eur Respir J* 2020; 55.
- 488 4. Zenner D, Kruijshaar ME, Andrews N, Abubakar I. Risk of tuberculosis in pregnancy:  
489 a national, primary care-based cohort and self-controlled case series study. *Am J*  
490 *Respir Crit Care Med* 2012; 185: 779-784.
- 491 5. Mor G, Aldo P, Alvero AB. The unique immunological and microbial aspects of  
492 pregnancy. *Nat Rev Immunol* 2017; 17: 469-482.
- 493 6. Erlebacher A. Immunology of the Maternal-Fetal Interface. *Annual Review of*  
494 *Immunology* 2013; 31: 387-411.
- 495 7. Shah NM, Herasimtschuk AA, Boasso A, Benlahrech A, Fuchs D, Imami N, Johnson  
496 MR. Changes in T Cell and Dendritic Cell Phenotype from Mid to Late Pregnancy  
497 Are Indicative of a Shift from Immune Tolerance to Immune Activation. *Front*  
498 *Immunol* 2017; 8: 1138.
- 499 8. Aghaeepour N, Ganio EA, McIlwain D, Tsai AS, Tingle M, Van Gassen S, Gaudilliere  
500 DK, Baca Q, McNeil L, Okada R, Ghaemi MS, Furman D, Wong RJ, Winn VD,

- 501 Druzin ML, El-Sayed YY, Quaintance C, Gibbs R, Darmstadt GL, Shaw GM,  
502 Stevenson DK, Tibshirani R, Nolan GP, Lewis DB, Angst MS, Gaudilliere B. An  
503 immune clock of human pregnancy. *Sci Immunol* 2017; 2.
- 504 9. Kourtis AP, Read JS, Jamieson DJ. Pregnancy and Infection. *New England Journal*  
505 *of Medicine* 2014; 370: 2211-2218.
- 506 10. Racicot K, Mor G. Risks associated with viral infections during pregnancy. *J Clin*  
507 *Invest* 2017; 127: 1591-1599.
- 508 11. Kay AW, Fukuyama J, Aziz N, Dekker CL, Mackey S, Swan GE, Davis MM, Holmes  
509 S, Blish CA. Enhanced natural killer-cell and T-cell responses to influenza A virus  
510 during pregnancy. *Proc Natl Acad Sci U S A* 2014; 111: 14506-14511.
- 511 12. Leveton C, Barnass S, Champion B, Lucas S, De Souza B, Nicol M, Banerjee D,  
512 Rook G. T-cell-mediated protection of mice against virulent *Mycobacterium*  
513 *tuberculosis*. *Infection and immunity* 1989; 57: 390-395.
- 514 13. Sakai S, Mayer-Barber KD, Barber DL. Defining features of protective CD4 T cell  
515 responses to *Mycobacterium tuberculosis*. *Curr Opin Immunol* 2014; 29: 137-  
516 142.
- 517 14. Müller I, Cobbold S, Waldmann H, Kaufmann S. Impaired resistance to  
518 *Mycobacterium tuberculosis* infection after selective in vivo depletion of L3T4+  
519 and Lyt-2+ T cells. *Infection and immunity* 1987; 55: 2037-2041.
- 520 15. Lin PL, Rutledge T, Green AM, Bigbee M, Fuhrman C, Klein E, Flynn JL. CD4 T cell  
521 depletion exacerbates acute *Mycobacterium tuberculosis* while reactivation of  
522 latent infection is dependent on severity of tissue depletion in cynomolgus  
523 macaques. *AIDS Res Hum Retroviruses* 2012; 28: 1693-1702.

- 524 16. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on  
525 incidence of tuberculosis in South Africa: a cohort study. *The Lancet* 2002; 359:  
526 2059-2064.
- 527 17. Sakai S, Kauffman KD, Sallin MA, Sharpe AH, Young HA, Ganusov VV, Barber DL.  
528 CD4 T Cell-Derived IFN-gamma Plays a Minimal Role in Control of Pulmonary  
529 Mycobacterium tuberculosis Infection and Must Be Actively Repressed by PD-1  
530 to Prevent Lethal Disease. *PLoS Pathog* 2016; 12: e1005667.
- 531 18. Forbes EK, Sander C, Ronan EO, McShane H, Hill AV, Beverley PC, Tchilian EZ.  
532 Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not  
533 spleen, correlate with protection against Mycobacterium tuberculosis aerosol  
534 challenge in mice. *The Journal of Immunology* 2008; 181: 4955-4964.
- 535 19. Lindenstrom T, Knudsen NP, Agger EM, Andersen P. Control of chronic  
536 mycobacterium tuberculosis infection by CD4 KLRG1- IL-2-secreting central  
537 memory cells. *J Immunol* 2013; 190: 6311-6319.
- 538 20. Andersen P, Urdahl KB. TB vaccines; promoting rapid and durable protection in the  
539 lung. *Curr Opin Immunol* 2015; 35: 55-62.
- 540 21. Grotzke JE, Lewinsohn DM. Role of CD8(+) T lymphocytes in control of  
541 Mycobacterium tuberculosis infection. *Microbes and Infection* 2005; 7: 776-788.
- 542 22. Lancioni C, Nyendak M, Kiguli S, Zalwango S, Mori T, Mayanja-Kizza H, Balyejusa  
543 S, Null M, Baseke J, Mulindwa D, Byrd L, Swarbrick G, Scott C, Johnson DF,  
544 Malone L, Mudido-Musoke P, Boom WH, Lewinsohn DM, Lewinsohn DA. CD8+  
545 T cells provide an immunologic signature of tuberculosis in young children. *Am J*  
546 *Resp Crit Care* 2012; 185: 206-212.

- 547 23. Fletcher HA, Snowden MA, Landry B, Rida W, Satti I, Harris SA, Matsumiya M,  
548 Tanner R, O'Shea MK, Dheenadhayalan V, Bogardus L, Stockdale L, Marsay L,  
549 Chomka A, Harrington-Kandt R, Manjaly-Thomas ZR, Naranbhai V, Stylianou E,  
550 Darboe F, Penn-Nicholson A, Nemes E, Hatherill M, Hussey G, Mahomed H,  
551 Tameris M, McClain JB, Evans TG, Hanekom WA, Scriba TJ, McShane H. T-cell  
552 activation is an immune correlate of risk in BCG vaccinated infants. *Nat Commun*  
553 2016; 7: 11290.
- 554 24. Adekambi T, Ibegbu CC, Cagle S, Kalokhe AS, Wang YF, Hu Y, Day CL, Ray SM,  
555 Rengarajan J. Biomarkers on patient T cells diagnose active tuberculosis and  
556 monitor treatment response. *J Clin Invest* 2015; 125: 1827-1838.
- 557 25. Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, Tappero JW,  
558 Bukusi EA, Cohen CR, Katabira E, Ronald A, Tumwesigye E, Were E, Fife KH,  
559 Kiarie J, Farquhar C, John-Stewart G, Kakia A, Odoyo J, Mucunguzi A, Nakku-  
560 Joloba E, Twesigye R, Ngure K, Apaka C, Tamoooh H, Gabona F, Mujugira A,  
561 Panteleeff D, Thomas KK, Kidoguchi L, Krows M, Revall J, Morrison S, Haugen  
562 H, Emmanuel-Ogier M, Ondrejcek L, Coombs RW, Frenkel L, Hendrix C,  
563 Bumpus NN, Bangsberg D, Haberer JE, Stevens WS, Lingappa JR, Celum C.  
564 Antiretroviral Prophylaxis for HIV Prevention in Heterosexual Men and Women.  
565 *New England Journal of Medicine* 2012; 367: 399-410.
- 566 26. Shah JA, Musvosvi M, Shey M, Horne DJ, Wells RD, Peterson GJ, Cox JS, Daya M,  
567 Hoal EG, Lin L, Gottardo R, Hanekom WA, Scriba TJ, Hatherill M, Hawn TR. A  
568 Functional TOLLIP Variant is Associated with BCG-Specific Immune Responses  
569 and Tuberculosis. *Am J Respir Crit Care Med* 2017.

- 570 27. Lin L, Finak G, Ushey K, Seshadri C, Hawn TR, Frahm N, Scriba TJ, Mahomed H,  
571 Hanekom W, Bart PA, Pantaleo G, Tomaras GD, Rerks-Ngarm S, Kaewkungwal  
572 J, Nitayaphan S, Pitisuttithum P, Michael NL, Kim JH, Robb ML, O'Connell RJ,  
573 Karasavvas N, Gilbert P, S CDR, McElrath MJ, Gottardo R. COMPASS identifies  
574 T-cell subsets correlated with clinical outcomes. *Nat Biotechnol* 2015; 33: 610-  
575 616.
- 576 28. Tesfa L, Koch FW, Pankow W, Volk HD, Kern F. Confirmation of Mycobacterium  
577 tuberculosis infection by flow cytometry after ex vivo incubation of peripheral  
578 blood T cells with an ESAT-6-derived peptide pool. *Cytometry Part B: Clinical*  
579 *Cytometry: The Journal of the International Society for Analytical Cytology* 2004;  
580 60: 47-53.
- 581 29. Papageorgiou CV, Anastasopoulos A, Ploussi M, Leventopoulos M, Karabela S,  
582 Fotiadis K, Papavasileiou A, Vogiatzakis E, Ioakeimidis D, Gritzapis AD, Poulakis  
583 N. Flow cytometry analysis of CD4+IFN-gamma+ T-cells for the diagnosis of  
584 mycobacterium tuberculosis infection. *Cytometry B Clin Cytom* 2016; 90: 303-  
585 311.
- 586 30. Lee J, Lee SY, Won DI, Cha SI, Park JY, Kim CH. Comparison of whole-blood  
587 interferon-gamma assay and flow cytometry for the detection of tuberculosis  
588 infection. *J Infect* 2013; 66: 338-345.
- 589 31. Sauzullo I, Scrivo R, Mengoni F, Ermocida A, Coppola M, Valesini G, Vullo V,  
590 Mastroianni CM. Multi-functional flow cytometry analysis of CD4+ T cells as an  
591 immune biomarker for latent tuberculosis status in patients treated with tumour  
592 necrosis factor (TNF) antagonists. *Clin Exp Immunol* 2014; 176: 410-417.



- 593 32. Mathad JS, Gupta A. Tuberculosis in Pregnant and Postpartum Women:  
594 Epidemiology, Management, and Research Gaps. *Clinical Infectious Diseases*  
595 2012; 55: 1532-1549.
- 596 33. Lu LL, Smith MT, Yu KKQ, Luedemann C, Suscovich TJ, Grace PS, Cain A, Yu WH,  
597 McKittrick TR, Lauffenburger D, Cummings RD, Mayanja-Kizza H, Hawn TR,  
598 Boom WH, Stein CM, Fortune SM, Seshadri C, Alter G. IFN- $\gamma$ -independent  
599 immune markers of Mycobacterium tuberculosis exposure. *Nat Med* 2019; 25:  
600 977-987.
- 601 34. LaCourse SM, Cranmer LM, Matemo D, Kinuthia J, Richardson BA, Horne DJ,  
602 John-Stewart G. Effect of Pregnancy on Interferon Gamma Release Assay and  
603 Tuberculin Skin Test Detection of Latent TB Infection Among HIV-Infected  
604 Women in a High Burden Setting. *J Acquir Immune Defic Syndr* 2017; 75: 128-  
605 136.
- 606 35. Lin PL, Flynn JL. CD8 T cells and Mycobacterium tuberculosis infection. *Semin*  
607 *Immunopathol* 2015; 37: 239-249.
- 608 36. Tsuyuzaki M, Igari H, Okada N, Suzuki K. Role of CD8 T-cell in immune response to  
609 tuberculosis-specific antigen in QuantiFERON-TB Gold Plus. *J Infect Chemother*  
610 2020; 26: 570-574.
- 611 37. Seder RA, Darrah PA, Roederer M. T-cell quality in memory and protection:  
612 implications for vaccine design. *Nat Rev Immunol*; 2008. p. 247-258.
- 613 38. Jameson SC, Masopust D. Understanding Subset Diversity in T Cell Memory.  
614 *Immunity* 2018; 48: 214-226.

- 615 39. Lindenstrøm T, Knudsen NPH, Agger EM, Andersen P. Control of chronic  
616 Mycobacterium tuberculosis infection by CD4 KLRG1– IL-2–secreting central  
617 memory cells. *The Journal of Immunology* 2013; 190: 6311-6319.
- 618 40. Vogelzang A, Perdomo C, Zedler U, Kuhlmann S, Hurwitz R, Gengenbacher M,  
619 Kaufmann SH. Central memory CD4+ T cells are responsible for the recombinant  
620 bacillus Calmette-Guerin  $\Delta$  ureC:: hly vaccine's superior protection against  
621 tuberculosis. *The Journal of infectious diseases* 2014; 210: 1928-1937.
- 622 41. Fletcher HA, Snowden MA, Landry B, Rida W, Satti I, Harris SA, Matsumiya M,  
623 Tanner R, O'Shea MK, Dheenadhayalan V, Bogardus L, Stockdale L, Marsay L,  
624 Chomka A, Harrington-Kandt R, Manjaly-Thomas ZR, Naranbhai V, Stylianou E,  
625 Darboe F, Penn-Nicholson A, Nemes E, Hatheril M, Hussey G, Mahomed H,  
626 Tameris M, McClain JB, Evans TG, Hanekom WA, Scriba TJ, McShane H. T-cell  
627 activation is an immune correlate of risk in BCG vaccinated infants. *Nat Commun*  
628 2016; 7: 11290.
- 629 42. Arenas-Hernandez M, Romero R, Xu Y, Panaitescu B, Garcia-Flores V, Miller D,  
630 Ahn H, Done B, Hassan SS, Hsu CD, Tarca AL, Sanchez-Torres C, Gomez-  
631 Lopez N. Effector and Activated T Cells Induce Preterm Labor and Birth That Is  
632 Prevented by Treatment with Progesterone. *J Immunol* 2019; 202: 2585-2608.
- 633 43. Mathad JS, Bhosale R, Sangar V, Mave V, Gupte N, Kanade S, Nangude A,  
634 Chopade K, Suryavanshi N, Deshpande P, Kulkarni V, Glesby MJ, Fitzgerald D,  
635 Bharadwaj R, Sambarey P, Gupta A. Pregnancy differentially impacts  
636 performance of latent tuberculosis diagnostics in a high-burden setting. *PLoS*  
637 *One* 2014; 9: e92308.

- 638 44. Mathad JS, Bhosale R, Balasubramanian U, Kanade S, Mave V, Suryavanshi N,  
639 Gupte N, Joshi S, Chandanwale A, Dupnik KM, Kulkarni V, Deshpande P,  
640 Fitzgerald DW, Gupta A. Quantitative IFN-gamma and IL-2 Response Associated  
641 with Latent Tuberculosis Test Discordance in HIV-infected Pregnant Women. *Am*  
642 *J Respir Crit Care Med* 2016; 193: 1421-1428.
- 643 45. Lancioni C, Nyendak M, Kiguli S, Zalwango S, Mori T, Mayanja-Kizza H, Balyejusa  
644 S, Null M, Baseke J, Mulindwa D, Byrd L, Swarbrick G, Scott C, Johnson DF,  
645 Malone L, Mudido-Musoke P, Boom WH, Lewinsohn DM, Lewinsohn DA, Unit  
646 TR. CD8+ T Cells Provide an Immunologic Signature of Tuberculosis in Young  
647 Children. *Am J Resp Crit Care* 2012; 185: 206-212.
- 648 46. Lewinsohn DM, Tydeman IS, Frieder M, Grotzke JE, Lines RA, Ahmed S, Prongay  
649 KD, Primack SL, Colgin LMA, Lewis AD, Lewinsohn DA. High resolution  
650 radiographic and fine immunologic definition of TB disease progression in the  
651 rhesus macaque. *Microbes and Infection* 2006; 8: 2587-2598.
- 652 47. Billeskov R, Vingsbo-Lundberg C, Andersen P, Dietrich J. Induction of CD8 T Cells  
653 against a Novel Epitope in TB10.4: Correlation with Mycobacterial Virulence and  
654 the Presence of a Functional Region of Difference-1. *The Journal of Immunology*  
655 2007; 179: 3973-3981.
- 656 48. Lewinsohn DA, Heinzl AS, Gardner JM, Zhu L, Alderson MR, Lewinsohn DM.  
657 Mycobacterium tuberculosis-specific CD8+ T Cells Preferentially Recognize  
658 Heavily Infected Cells. *Am J Resp Crit Care* 2003; 168: 1346-1352.

- 659 49. Zenclussen AC, Hämmerling GJ. Cellular Regulation of the Uterine  
660 Microenvironment That Enables Embryo Implantation. *Front Immunol* 2015; 6:  
661 321.
- 662 50. Gnainsky Y, Granot I, Aldo P, Barash A, Or Y, Mor G, Dekel N. Biopsy-induced  
663 inflammatory conditions improve endometrial receptivity: the mechanism of  
664 action. *Reproduction* 2015; 149: 75-85.
- 665 51. Gupta A, Montepiedra G, Aaron L, Theron G, McCarthy K, Bradford S, Chipato T,  
666 Vhembo T, Stranix-Chibanda L, Onyango-Makumbi C, Masheto GR, Violari A,  
667 Mmbaga BT, Aurpibul L, Bhosale R, Mave V, Rouzier V, Hesselning A, Shin K,  
668 Zimmer B, Costello D, Sterling TR, Chakhtoura N, Jean-Philippe P, Weinberg A,  
669 Team IPTBAS. Isoniazid Preventive Therapy in HIV-Infected Pregnant and  
670 Postpartum Women. *New England Journal of Medicine* 2019; 381: 1333-1346.  
671

672 **Table 1. Baseline characteristics of participants and timing of samples with evaluable results**

Characteristic	Overall	LTBI+*	LTBI-	RR (95% CI)	p
	Median (IQR) or n (%)	Median (IQR) or n (%)	Median (IQR) or n (%)		
<b>Baseline</b>	<b>N=49**</b>	<b>N=19</b>	<b>N=30</b>		
Age (years)	26.4 (23.2-31.3)	26.8 (23.2-31.1)	26.2 (22.7-31.5)	1.02 (0.94-1.10)	0.624
WLHIV	18 (36.7)	6 (31.6)	12 (40.0)	0.79 (0.36-1.74)	0.565
CD4 (cells/mm <sup>3</sup> )	765.5 (507-1070)	868.5 (588-1272)	730.5 (476.5-1042)	1.00 (1.00-1.00)	0.258
<b>Samples</b>	<b>N=117</b>	<b>N=48</b>	<b>N=69</b>		
<b>Pregnancy stage</b>				1.10 (0.83-1.47)	0.496
Pre-pregnancy <sup>^</sup>	48 (41.0)	18 (37.5)	30 (43.5)		
Pregnancy	47 (40.2)	20 (41.7)	27 (39.1)	0.77 (0.52-1.14)	0.184
1 <sup>st</sup> trimester (0 to <14 weeks)	9 (19.2)	5 (25.0)	4 (14.8)		
2 <sup>nd</sup> trimester (14 to <28 weeks)	14 (29.8)	7 (35.0)	7 (25.9)		
3 <sup>rd</sup> trimester (≥28 weeks)	24 (51.1)	8 (40.0)	16 (59.3)		
Post-pregnancy <sup>***</sup>	22 (18.8)	10 (20.8)	12 (17.4)		
<b>Timing of sample collection (weeks)</b>					
Pre-pregnancy	-18.7 (-22.2 – -12.4)	-18.3 (-22.3 – -11.7)	-18.8 (-22.1 – -13.1)	1.00 (0.96-1.03)	0.836
During pregnancy	26.9 (12.7-30.9)	18.9 (11.7-28.1)	28.7 (22.4-32.0)	0.97 (0.94-1.00)	0.077
Post-pregnancy	23.1 (18.4-39.6)	19.5 (17.3-45.6)	30.5 (21.4-38.7)	1.00 (0.97-1.03)	0.980

673 Abbreviations: WLHIV-People living with HIV, LTBI-Latent Tuberculosis Infection, RR-Relative Risk

674 \* LTBI diagnosis determined by 2x increase of frequency of IFNγ+CD4+ cells after stimulation with Mtb antigens over control

675 \*\* Includes one participant whose pre-pregnancy sample was unevaluable


676 \*\*\* Up to six months after delivery

677 <sup>^</sup> Samples collected up to six months before date of conception


678




A




B




C




D




E




F




B




A













Figure 6









Figure 8

	Pre-pregnancy	1 <sup>st</sup> Trimester	2 <sup>nd</sup> trimester	3 <sup>rd</sup> trimester	postpartum
Mtb-specific T-cells					
CD4+	↔	↔	↓	↓↓↓	↔
CD8+	↓↓↓	↓↓	↑↑	↑	↓↓
Mitogen stimulated T-cells					
CD4+	↔	↔	↔	↑↓	↓↑
CD8+	↔	↔	↑	↔	↔
Nonspecific T-cell activation					
Activated T-cells	↔	↓	↑↑	↑↑↑	↑